From the YMB:

“Feasibility study with artificial pancreas

Check out the companies involved. Clinical trial NCT01874392. Google it”

http://finance.yahoo.com/mb/MNKD/#mbt=Feasibility%2520st%25u2026&mbl=http%253A%2F%2Ffinance.yahoo.com%2Fmbview%2Fthreadview%2F%253B_ylt%253DAiU0R1ZzkQGN1uqcUbb9kIPeAohG%253B_ylu%253DX3oDMTB2Y252cDRkBHBvcwMxOQRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-%253B_ylg%253DX3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-%253B_ylv%253D3%253F%2526bn%253D0243242e-59fb-3abc-8d27-962c7bf26a1d%2526tid%253D1376053762119-c86002e6-2584-4573-8a72-7674da9e2a0d%2526tls%253Dla%25252Cd%25252C0%25252C3&mbtc=mb-tab-topic

From http://clinicaltrials.gov/show/NCT01874392

“This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System by MannKind Corporation). The goal of this proposed study is to explore the feasibility of using multiple insulin delivery routes in order to mimic the physiology of both first- and second-phase insulin secretion. The intent is to exploit the rapid action achieved by inhaled insulin to compensate for part of the meals and utilize the conventional subcutaneous route for management of basal insulin and as second-phase meal-related insulin.”

This is something that I would have expected long ago. Consider, if the hypoglycemic events when using Lantus with Afrezza is from the Lantus, as Al has said, doesn’t combining Afrezza for the prandial insulin with an insulin pump for the basal insulin make sense? It seems to me that this combination would produce the best results.

I am not a doctor and the following is pure speculation on my part

Lantus does not last a full 24 hours. I have read that it is better to take two Lantus injection per day so that the basal insulin level is more uniform.

If the basal insulin is more uniform throughout the day, it seems to me that you could titrate the dose so that fasting plasma glucose levels are on average lower. If the Lantus from a single injection is wearing off in the early morning, then glucose control cannot be as good at that time.

This average lower glucose level could also be obtained with a lower level of basal insulin during the day since you don’t have to compensate for the declining level of the basal insulin from the time of the morning injection up until the next morning.

With a lower basal level of basal insulin, wouldn’t the chance of a hypoglycemic event be lower, since the tail from the Afrezza is combined with a lower basal insulin level?

Any comments?

Thanks,

Bob